Fig. 2.
![Fig. 2. Annual hazard rates of end-stage liver disease (ESLD) among hepatitis C virus (HCV)– and HIV-seropositive participants with complete data in the MHCS. / By age group ([A] n = 1192), hepatitis B virus (HBV) status ([B] n = 1180), and CD4+ lymphocyte count ([C] n = 1049).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/100/5/10.1182_blood.v100.5.1584.h81702001584_1584_1589/3/h81723060002.jpeg?Expires=1736062988&Signature=lEL-fZoY2mk7qIrPbbXz3cD1nl~l4N6CtppvNL5UOGWjgoXKKyEkvHwKsoQTjV9o6JE7KgU1wbp6KiYrcxx5fxW-ayBVQElqQdDjhlyFljHKlwx4Ng8f6FpAYP0q5R24SVt9SOFdMWZyDmM9RyfLLjMEHofnCDMXMiYwuRYJWLDYdRMj-dvpkavEN0-DXzocTtcOXdQiKfv6iZxFtYMjE1SWsEGO92RfyZ-Cp0Z4w~Tu8A2va2TQ4KELB4bJP0OK8DQCuueS59SuvXyIlo0BCYZzex2ZwFbZnD0NKYkbPg4dbRnhhT1oqK42LTOO~zA1uO8-G8M9vgYVupjm3RMtDA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Annual hazard rates of end-stage liver disease (ESLD) among hepatitis C virus (HCV)– and HIV-seropositive participants with complete data in the MHCS.
By age group ([A] n = 1192), hepatitis B virus (HBV) status ([B] n = 1180), and CD4+ lymphocyte count ([C] n = 1049).
